Transcutaneous immunization with a 40-kDa outer membrane protein of Porphyromonas gingivalis induces specific antibodies which inhibit coaggregation by P. gingivalis

Maeba, Satomi; Otake, Shigeo; Namikoshi, Jun; Shibata, Yasuko; Hayakawa, Mitsuo; Abiko, Yoshimitsu; Yamamoto, Masafumi

doi:10.1016/j.vaccine.2004.10.036

Cited by 43 publications

(29 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Briefly, salivary glands were carefully excised, teased apart, and dissociated using 0.3 mg/ml collagenase (Nitta Gelatin Co. Ltd., Osaka, Japan) in RPMI 1640 (Wako Pure Chemical Industries Ltd., Osaka, Japan). Mononuclear cells were obtained at the interface of the 50% and 75% layers of a discontinuous Percoll gradient (GE Healthcare UK, Ltd., Little Chalfont, United Kingdom) (36). To assess numbers of antigenspecific antibody-forming cells, an enzyme-linked immunospot (ELISPOT) assay was performed as described previously (57).…”

Section: Assessment Of Antibody-forming Cellsmentioning

confidence: 99%

Nasal Immunization with a Fusion Protein Consisting of the Hemagglutinin A Antigenic Region and the Maltose-Binding Protein Elicits CD11c⁺CD8⁺Dendritic Cells for Induced Long-Term Protective Immunity

Hashizume

Kurita‐Ochiai

et al. 2011

Infect Immun

Self Cite

View full text Add to dashboard Cite

We assessed the efficacy of a fusion protein consisting of the 25-kDa antigenic region of Porphyromonas gingivalis hemagglutinin A and the Escherichia coli maltose-binding protein (25k-hagA-MBP) as a nasal vaccine for the prevention of oral infection with P. gingivalis. Nasal immunization with 25k-hagA-MBP induced high levels of 25k-hagA-specific serum IgG, serum IgA, and salivary IgA antibodies in a Toll-like receptor 4 (TLR4)-dependent manner. These antibody responses were maintained for at least 1 year after immunization. Analysis of cytokine responses showed that nasal administration of 25k-hagA-MBP induced antigen-specific CD4 ؉ T cells producing interleukin 4 (IL-4) and IL-5, but not gamma interferon (IFN-␥), in the spleen and cervical lymph nodes (CLNs). Furthermore, increased numbers of CD11c؉ , dendritic cells with upregulated expression of CD80, CD86, CD40, and major histocompatibility complex class II (MHC II) molecules were noted in the spleen, CLNs, and nasopharynx-associated lymphoreticular tissues (NALT). Interestingly, when 25k-hagA-MBP or cholera toxin (CT) was given intranasally to enable examination of their presence in neuronal tissues, the amounts of 25k-hagA-MBP were significantly lower than those of CT. Importantly, mice given 25k-hagA-MBP nasally showed a significant reduction in alveolar bone loss caused by oral infection with P. gingivalis, even 1 year after the immunization. These results suggest that 25k-hagA-MBP administered nasally would be an effective and safe mucosal vaccine against P. gingivalis infection and may be an important tool for the prevention of chronic periodontitis in humans.

show abstract

Section: Assessment Of Antibody-forming Cellsmentioning

confidence: 99%

Nasal Immunization with a Fusion Protein Consisting of the Hemagglutinin A Antigenic Region and the Maltose-Binding Protein Elicits CD11c⁺CD8⁺Dendritic Cells for Induced Long-Term Protective Immunity

Hashizume

Kurita‐Ochiai

et al. 2011

Infect Immun

Self Cite

View full text Add to dashboard Cite

show abstract

“…Cells from gingival tissues were prepared by being gentlyteasedthrough sterile stainless steel screens, followed by an enzymatic dissociation procedure with 0.3 mg/ml collagenase (Nitta Gelatin Co., Ltd., Osaka, Japan) in RPMI-1640 (Wako Pure Chemical Industries Ltd., Osaka, Japan) (14). GMCs were purified on discontinuous Percoll gradients (GE Healthcare UK, Ltd., Little Chalfont, UK) (15,16), and were re-suspended in RPMI 1640 (Cellgro Mediatech, Washington, DC) supplemented with HEPES buffer (15 mM), L-glutamine (2 mM), penicillin (100 U/mL), streptomycin (100 mg/mL), and 10% fetal calf serum (FCS) (complete medium).…”

Section: Isolation Of Gingival Mononuclear Cells (Gmcs)mentioning

confidence: 99%

Characterization of Inflammation-derived CD11c+ Dendritic Cells in Mouse Model of Periodontal Disease

et al. 2013

Self Cite

View full text Add to dashboard Cite

show abstract

“…As visualized in Anti-r40-kDa OMP hMAb Oral Rat Protects against P. gingivalis-induced alveolar bone loss [81] 40-kDa OMP and CT tc., in. Mouse Induced serum IgG, IgA and IgG in saliva [82,83] 40-kDa OMP tc. Rat Induced serum IgG, IgA and IgG in saliva.…”

Section: Immunization With P Gingivalis-specific Antigensmentioning

confidence: 99%

Feasibility and therapeutic strategies of vaccines againstPorphyromonas gingivalis

Jong¹,

Reijden²

2010

Expert Review of Vaccines

View full text Add to dashboard Cite

Periodontitis is a chronic infectious disease that is highly prevalent worldwide and is characterized by inflammation of the gums, and loss of connective tissue and bone support. The Gramnegative anerobic bacterium Porphyromonas gingivalis is generally accepted as the main etiological agent for chronic periodontitis. The objective of this paper is to elucidate the feasibility of achieving protection against periodontitis though immunization against P. gingivalis. Until now, animal studies have showed no complete protection against P. gingivalis. However, current knowledge about P. gingivalis structures could be applicable for further research to develop a successful licensed vaccine and alternative therapeutic strategies. This review reveals that a multicomponent vaccine against P. gingivalis, which includes structures shared among P. gingivalis serotypes, will be feasible to induce broad and complete protection. Keywords: capsule • fimbriae • gingipain • immunization • periodontitis • Porphyromonas gingivalis • vaccineFeasibility and therapeutic strategies of vaccines against Porphyromonas gingivalis Expert Rev. Vaccines 9(2), 193-208 (2010) For reprint orders, please contact reprints@expert-reviews.com Expert Rev. Vaccines 9(2), (2010)

show abstract

Transcutaneous immunization with a 40-kDa outer membrane protein of Porphyromonas gingivalis induces specific antibodies which inhibit coaggregation by P. gingivalis

Cited by 43 publications

References 54 publications

Nasal Immunization with a Fusion Protein Consisting of the Hemagglutinin A Antigenic Region and the Maltose-Binding Protein Elicits CD11c⁺CD8⁺Dendritic Cells for Induced Long-Term Protective Immunity

Nasal Immunization with a Fusion Protein Consisting of the Hemagglutinin A Antigenic Region and the Maltose-Binding Protein Elicits CD11c⁺CD8⁺Dendritic Cells for Induced Long-Term Protective Immunity

Characterization of Inflammation-derived CD11c+ Dendritic Cells in Mouse Model of Periodontal Disease

Feasibility and therapeutic strategies of vaccines againstPorphyromonas gingivalis

Contact Info

Product

Resources

About

Transcutaneous immunization with a 40-kDa outer membrane protein of Porphyromonas gingivalis induces specific antibodies which inhibit coaggregation by P. gingivalis

Cited by 43 publications

References 54 publications

Nasal Immunization with a Fusion Protein Consisting of the Hemagglutinin A Antigenic Region and the Maltose-Binding Protein Elicits CD11c+CD8+Dendritic Cells for Induced Long-Term Protective Immunity

Nasal Immunization with a Fusion Protein Consisting of the Hemagglutinin A Antigenic Region and the Maltose-Binding Protein Elicits CD11c+CD8+Dendritic Cells for Induced Long-Term Protective Immunity

Characterization of Inflammation-derived CD11c+ Dendritic Cells in Mouse Model of Periodontal Disease

Feasibility and therapeutic strategies of vaccines againstPorphyromonas gingivalis

Contact Info

Product

Resources

About

Nasal Immunization with a Fusion Protein Consisting of the Hemagglutinin A Antigenic Region and the Maltose-Binding Protein Elicits CD11c⁺CD8⁺Dendritic Cells for Induced Long-Term Protective Immunity

Nasal Immunization with a Fusion Protein Consisting of the Hemagglutinin A Antigenic Region and the Maltose-Binding Protein Elicits CD11c⁺CD8⁺Dendritic Cells for Induced Long-Term Protective Immunity